ABSTRACT:
RNA has emerged as a critical tool in modern biotechnology and therapeutics, with applications ranging from vaccine development to gene therapy. mRNA is synthesized by in vitro transcription using single-subunit RNA polymerases, whose performance directly influences the quality of the mRNA produced. RNA polymerase performance varies significantly depending on template format (linear, circular, self-amplifying), sequence, as well as cap analog and nucleotide chemistries. To meet the needs of RNA therapeutic manufacturing, Primrose Bio has developed a panel of RNA polymerases (Prima RNApols) with superior performance, including high yield, transcript integrity, capping efficiency, and low dsRNA formation. This panel of improved enzymes serves as superior mRNA synthesis options for applications requiring high-quality mRNA produced at a lower cost.
To meet customer needs for specific drugs and mRNA manufacturing budgets, Primrose Bio has also developed advanced capabilities in custom ultra high throughput enzyme evolution. Using our proprietary and highly efficient screening and testing platform, we are able to rapidly improve and customize RNA polymerases to meet industry and customer specific needs, further enabling the next generation of RNA-based therapeutics.